CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
Schall, Brown & Schwartz LLP issued a shareholder-solicitation notice regarding a class action lawsuit against Capricor Therapeutics. The complaint alleges Capricor misled the market by changing the statistical analysis plan for Deramiocel without FDA agreement before BLA resubmission.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.